Knottins: disulfide-bonded therapeutic and diagnostic peptides

Craik, 2007, Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins, Expert Opin. Invest. Drugs, 16, 595, 10.1517/13543784.16.5.595 Kolmar, 2009, Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins, Curr. Opin. Pharmacol., 9, 608, 10.1016/j.coph.2009.05.004 Kolmar, 2010, Engineered cystine-knot miniproteins for diagnostic applications, Expert Rev. Mol. Diagn., 10, 361, 10.1586/erm.10.15 Kolmar, 2008, Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins, FEBS J., 275, 2684, 10.1111/j.1742-4658.2008.06440.x Gracy, 2008, KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007, Nucleic Acids Res., 36, D314, 10.1093/nar/gkm939 Williams, 2008, Ziconotide: an update and review, Expert Opin. Pharmacother., 9, 1575, 10.1517/14656566.9.9.1575 Ollmann, 1997, Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein, Science, 278, 135, 10.1126/science.278.5335.135 Joppa, 2007, Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83–132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice, Peptides, 28, 636, 10.1016/j.peptides.2006.11.021 Pysz, 2010, Molecular imaging: current status and emerging strategies, Clin. Radiol., 65, 500, 10.1016/j.crad.2010.03.011 Veiseh, 2007, Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci, Cancer Res., 67, 6882, 10.1158/0008-5472.CAN-06-3948 Christmann, 1999, The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides, Protein Eng., 12, 797, 10.1093/protein/12.9.797 Reiss, 2006, Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins, Platelets, 17, 153, 10.1080/09537100500436663 Kimura, 2009, Engineered cystine knot peptides that bind alphav beta3, alphav beta5, and alpha5 beta1 integrins with low-nanomolar affinity, Proteins, 77, 359, 10.1002/prot.22441 Lahti, 2009, Interrogating and predicting tolerated sequence diversity in protein folds: application to E elaterium trypsin inhibitor-II cystine-knot miniprotein, PLoS Comput. Biol., 5, e1000499, 10.1371/journal.pcbi.1000499 Silverman, 2011, Cystine-knot peptides engineered with specificities for alphaIIb beta3 or alphaIIb beta3 and alphav beta3 integrins are potent inhibitors of platelet aggregation, J. Mol. Recognit., 24, 127, 10.1002/jmr.1036 Silverman, 2009, Engineered cystine-knot peptides that bind alphav beta3 integrin with antibody-like affinities, J. Mol. Biol., 385, 1064, 10.1016/j.jmb.2008.11.004 Krause, 2007, Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists, FEBS J., 274, 86, 10.1111/j.1742-4658.2006.05567.x Werle, 2006, The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery, J. Drug Target., 14, 137, 10.1080/10611860600648254 Kimura, 2009, Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects, Cancer Res., 69, 2435, 10.1158/0008-5472.CAN-08-2495 Jiang, 2010, Evaluation of a 64Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin, J. Nucl. Med., 51, 251, 10.2967/jnumed.109.069831 Miao, 2009, An engineered knottin peptide labeled with 18F for PET imaging of integrin expression, Bioconjug. Chem., 20, 2342, 10.1021/bc900361g Nielsen, 2010, PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide, Cancer Res., 70, 9022, 10.1158/0008-5472.CAN-10-1338 Miao, 2010, Protein scaffold-based molecular probes for cancer molecular imaging, Amino Acids Kimura, 2010, A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects, Bioconjug. Chem., 21, 436, 10.1021/bc9003102 Willmann, 2010, Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides, J. Nucl. Med., 51, 433, 10.2967/jnumed.109.068007 Jiang, 2010, Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy, Eur. J. Nucl. Med. Mol. Imaging, 38, 613, 10.1007/s00259-010-1684-x Daly, 2011, Bioactive cystine knot proteins, Curr. Opin. Chem. Biol., 15, 362, 10.1016/j.cbpa.2011.02.008 Wang, 2008, CyBase: a database of cyclic protein sequences and structures, with applications in protein discovery and engineering, Nucleic Acids Res., 36, D206, 10.1093/nar/gkm953 Greenwood, 2007, The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis, Int. J. Biochem. Cell Biol., 39, 2252, 10.1016/j.biocel.2007.06.016 Clark, 2006, Structural plasticity of the cyclic-cystine-knot framework: implications for biological activity and drug design, Biochem. J., 394, 85, 10.1042/BJ20051691 Gunasekera, 2008, Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides, J. Med. Chem., 51, 7697, 10.1021/jm800704e Thongyoo, 2009, Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold, J. Med. Chem., 52, 6197, 10.1021/jm901233u Clark, 2005, Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII, Proc. Natl. Acad. Sci. U.S.A., 102, 13767, 10.1073/pnas.0504613102 Clark, 2010, The engineering of an orally active conotoxin for the treatment of neuropathic pain, Angew. Chem. Int. Ed. Engl., 49, 6545, 10.1002/anie.201000620 Clark, 2010, Cyclization of conotoxins to improve their biopharmaceutical properties, Toxicon Akcan, 2011, Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy, J. Med. Chem., 54, 782, 10.1021/jm101018r Colgrave, 2004, Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot, Biochemistry, 43, 5965, 10.1021/bi049711q Heitz, 2008, Knottin cyclization: impact on structure and dynamics, BMC Struct. Biol., 8, 54, 10.1186/1472-6807-8-54 Gebauer, 2009, Engineered protein scaffolds as next-generation antibody therapeutics, Curr. Opin. Chem. Biol., 13, 245, 10.1016/j.cbpa.2009.04.627 Wu, 2005, Arming antibodies: prospects and challenges for immunoconjugates, Nat. Biotechnol., 23, 1137, 10.1038/nbt1141 Thurber, 2007, Theoretic criteria for antibody penetration into solid tumors and micrometastases, J. Nucl. Med., 48, 995, 10.2967/jnumed.106.037069 Chames, 2009, Therapeutic antibodies: successes, limitations and hopes for the future, Br. J. Pharmacol., 157, 220, 10.1111/j.1476-5381.2009.00190.x Justice, A. et al. [Neurex Corporation] (1999) Methods for producing analgesia. USP5859186 Bakker, A. et al. [Amgen Mountain View Inc.] (2010) IL-6 binding proteins. USP7786262 Silverman, 2005, Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains, Nat. Biotechnol., 23, 1556, 10.1038/nbt1166 Löfblom, 2010, Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications, FEBS Lett., 584, 2670, 10.1016/j.febslet.2010.04.014 Nilsson, F. et al. [Affibody AB] (2010) Polypeptides having binding affinity for Her2. US Patent application 20100048868 Bloom, 2009, FN3: a new protein scaffold reaches the clinic, Drug Discov. Today, 14, 949, 10.1016/j.drudis.2009.06.007 Yan, C. et al. [Bristol-Myers Squibb Company] (2010) Inhibitors of type 2 vascular endothelial growth factor receptors. USP7858739 Stumpp, 2008, DARPins: a new generation of protein therapeutics, Drug Discov. Today, 13, 695, 10.1016/j.drudis.2008.04.013 Tobias, S.M. et al. [University of Zurich] (2008) Collection of repeat proteins comprising repeat modules. USP7417130 Skerra, 2008, Alternative binding proteins: anticalins – harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities, FEBS J., 275, 2677, 10.1111/j.1742-4658.2008.06439.x Skerra, A. et al. [Pieres AG] (2011) Muteins of human tear lipocalin. USP7893208B2 Schmoldt, 2005, A fusion protein system for the recombinant production of short disulfide bond rich cystine knot peptides using barnase as a purification handle, Protein Expr. Purif., 39, 82, 10.1016/j.pep.2004.09.016 Tolmachev, 2008, Imaging of HER-2 overexpression in tumors for guiding therapy, Curr. Pharm. Des., 14, 2999, 10.2174/138161208786404290 Wu, 2000, High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment, Proc. Natl. Acad. Sci. U.S.A., 97, 8495, 10.1073/pnas.150228297 Zahnd, 2010, Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size, Cancer Res., 70, 1595, 10.1158/0008-5472.CAN-09-2724